[ 3 ] Gass JD, Little H. Bilateral bullous exudative retinal detachment complicating idiopathic central serous chorioretinopathy during systemic corticosteroid therapy[J]. Ophthalmology, 1995, 102(5): 737-747.
[4]
[ 4 ] TAP Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials-TAP report. Treatment of age-related macular degeneration with photodynamic therapy(TAP) study group[J]. Arch Ophthalmol, 1999, 117(10): 1329-1345.
[5]
[ 5 ] Allison BA, Pritchard PH, Levy JG. Evidence for low-density lipoprotein receptor-mediated uptake of benzoporphyrin derivative[J]. Br J Cancer, 1994, 69(5): 833-839.
[6]
[ 6 ] Engbrecht BW, Menon C, Kachur AV, et al. Photofrin-mediated photodynamic therapy induces vascular occlusion and apoptosis in a human sarcoma xenograft model[J]. Cancer Res, 1999, 59(17): 4334-4342.
[7]
[ 7 ] Tsujikawa A, Ojima Y, Yamashiro K, et al. Punctate hyperfluorescent spots associated with central serous chorioretinopathy as seen on indocyanine green angiography[J]. Retina, 2010, 30(5): 801-809.
Liew G, Quin G, Gillies M, et al. Central serous chorioretinopathy: a review of epidemiology and pathophysiology[J]. Clin Experiment Ophthalmol, 2013, 41(2): 201-214.
[12]
Chan WM, Lam DS, TYY Lai, et al. Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a novel treatment at the primary disease level[J]. Br J Ophthalmol, 2003, 87(12): 1453-1458.
[13]
Schmidt-Erfurth U, Michels S, Barbazetto I, et al. Photodynamic effects on choroidal neovascularization and physiological choroid[J]. Invest Ophthalmol Vis Sci, 2002, 43(3): 830-841.
[14]
Hajishengallis G, Arce S, Gockel CM, et al. Immunomodulation with enterotoxins for the generation of secretory immunity or tolerance: applications for oral infections[J]. J Dent Res, 2005, 84(12): 1104-1116.
[15]
Yannuzzi LA, Slakter JS, Gross NE, et al. Indocyanine green angiography-guided photodynamic therapy for treatment of chronic central serous chorioretinopathy: a pilot study. 2003[J]. Retina, 2012, 32 (Suppl 1): 288-298.
[16]
Cardillo Piccolino F, Eandi CM, Ventre L, et al. Photodynamic therapy for chronic central serous chorioretinopathy[J]. Retina, 2003, 23: 752-763.
[17]
Chan WM, Lai TY, Lai RY, et al. Safety enhanced photodynamic therapy for chronic central serous chorioretinopathy: one-year results of a prospective study[J]. Retina, 2008, 28(1): 85-93.
[18]
Haimovici R, Kramer M, Miller JW, et al. Localization of lipoprotein-delivered benzoporphyrin derivative in the rabbit eye[J]. Curr Eye Res, 1997, 16(2): 83-90.
[19]
Reibaldi M, Boscia F, Avitabile T, et al. Low-fluence photodynamic therapy in longstanding chronic central serous chorioretinopathy with foveal and gravitational atrophy[J]. Eur J Ophthalmol, 2009, 19(1): 154-158.
[20]
Zhao MW, Zhou P, Xiao HX, et al. Photodynamic therapy for acute central serous chorioretinopathy: the safe effective lowest dose of verteporfin[J]. Retina, 2009, 29(8): 1155-1161.
[21]
lnoue R, Sawa M, Tsujikawa M, et al. Association between the efficacy of photodynamic therapy and indocyanine green angiograph findings for central serous chorioretinopathy[J]. Am J Ophthalmol, 2009, 149: 441-446.
